Zyprexa By the Numbers
3—Studies conducted over an eight-year period by Dr. Elizabeth Koller; use of Zyprexa was linked to 289 cases of diabetes, 28 of them fatal.
13—States suing Lilly over Zyprexa for their citizens’ diabetes and weight gains.
16—Number of Zyprexa side effects: increased heartbeat, seizures, liver problems, low blood pressure, difficulty swallowing, sleepiness, weight gain, dry mouth, dizziness, restlessness, constipation, increased body temperature, upset stomach, increased appetite and tremors.
30%—Of Lilly’s profits derive from Zyprexa sales.
50%—Higher chance of patients developing diabetes on Zyprexa, as compared with older generation antipsychotics.
70—Clinical trials of Zyprexa showed that 16% of patients taking the drug gained more than 66 pounds—some of them as much as 100 pounds.
200—Pounds gained by plaintiff Dawn Zipper of Mesquite, Texas after one year on Zyprexa.
$250—Per month for most patients taking Zyprexa, considerably more than first-generation antipsychotic drugs.
1,200—Zyprexa lawsuits still pending against Lilly.
49,000—New prescriptions written after three months of Lilly’s “Viva Zyprexa” marketing campaign pitched the drug for purposes other than those approved by the Food and Drug Administration.
20 million—People worldwide who have taken Zyprexa since its market debut in 1996.
$100 million—Lawsuit filed by Mississippi against Lilly in 2006 for illegally marketing Zyprexa.
$500 million—Amount Eli Lilly agrees to pay in 2007 to settle 18,000 Zyprexa lawsuits.
$700 million—Paid by Lilly in 2005 to settle 8,000 lawsuits from people who had developed diabetes or other conditions after taking Zyprexa.
$1 billion—Sales of Zyprexa in 2002, in spite of studies showing possible links with diabetes.
$4.2 billion—Sales of Zyprexa in 2005.
$30 billion—Sales of Zyprexa since going on the market in 1996.